While homozygous or heterozygous compound mutations in PRKN lead to early-onset Parkinson’s disease (PD; Lücking et al., 2000), the role of heterozygous mutations is still controversial, ranging from benign condition to susceptibility factor (Marder et al., 2010; Moura et al., 2013). Here, PRKN is linked to Parkinson disease.